glp 1 retatrutide Promises Big Weight Loss, but Safety Remains a Question New GLP-1 obesity drug, retatrutide,

According to a 2024 study by Duo Do et al., reported that the use of a once-weekly GLP-1 receptor agonist was independently linked to a 30.5% higher prevalence of elevated residual gastric content on preprocedural gastric ultrasonography, which is a significant risk factor for aspiration during anesthesia

Low blood sugar (hypoglycemia): Your risk for getting low blood sugar may be higher if you use Tirzepatide with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin

Several observational studies have examined the potential association between GLP-1RAs and suicidality, with mixed findings regarding suicidal ideation, self-harm, and suicide risk [49]

it is simply a more convenient way to induce the same physiological trade-offs we have seen over the last several years with the shots

P = 0.35